



NDA 210237

**TENTATIVE APPROVAL**

Mylan Pharmaceuticals Inc.  
U.S. Agent of Mylan Laboratories Limited, India  
Attention: Shane Shupe  
Director, Regulatory Affairs  
781 Chestnut Ridge Road  
P.O. Box 4310  
Morgantown, WV 26504-4310

Dear Mr. Shupe:

Please refer to your New Drug Application (NDA) dated and received August 11, 2017, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for the following drug product:

- Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg

This NDA provides for the use of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets alone as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.

This NDA was reviewed under the President's Emergency Plan for AIDS Relief (PEPFAR).

We have completed our review of this application. It is tentatively approved under 21 CFR 314.105 for use as recommended in the agreed-upon enclosed labeling (text for the package insert and patient information submitted on February 9, 2018, and immediate container labels submitted on September 5, 2017) and with the minor editorial revisions listed below that were communicated to you on February 5, 2018. Based on the data provided, the expiration dating period is 24 months for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg in HDPE bottles containing 30 or 90 tablets with desiccant, induction seal, and non-child-resistant cap when stored below 30°C (86°F).

**Minor Editorial Revisions for the Package Insert**

- Keep "is" instead of "are" throughout the label when referring to the singular drug product "dolutegravir, emtricitabine and tenofovir alafenamide tablets"
- Keep subsections 8.6 for renal impairment and 8.7 for hepatic impairment in the HIGHLIGHTS and FULL PRESCRIBING INFORMATION

- Keep “in Adults” in subsection 12.3 in the CLINICAL PHARMACOLOGY section in the FULL PRESCRIBING INFORMATION
- Add “in Adults” in subsection 12.3 in the CLINICAL PHARMACOLOGY section in the TABLE OF CONTENTS
- Add “tablets” after “Dolutegravir, emtricitabine and tenofovir alafenamide...” in the INDICATION AND USAGE in the HIGHLIGHTS

This determination is based upon information available to the Agency at this time, [i.e., information in your application and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacture and testing of the drug product]. This determination is subject to change on the basis of any new information that may come to our attention.

The listed drugs [Tivicay (dolutegravir) and Descovy<sup>®</sup> (emtricitabine and tenofovir alafenamide)] upon which your application relies are subject to a period of patent and/or exclusivity protection and therefore, final approval of your application under section 505(c)(3) of the Act [21 U.S.C. 355(c)(3)] may not be made effective until the period has expired.

To obtain final approval of this application, submit an amendment two or six months prior to the: 1.) expiration of the patent(s) and/or exclusivity protection or 2.) date you believe that your NDA will be eligible for final approval, as appropriate. In your cover letter, clearly identify your amendment as **“REQUEST FOR FINAL APPROVAL.”** This amendment should provide the legal/regulatory basis for your request for final approval and should include a copy of any relevant court order or judgment settlement, or licensing agreement, as appropriate. In addition to a safety update, the amendment should also identify changes, if any, in the conditions under which your product was tentatively approved, i.e., updated labeling; chemistry, manufacturing, and controls data. This amendment should include draft final printed labels and labeling which comply with all U.S. regulations (uniqueness of drug product appearance per 21 CFR 206; child-resistant packaging per 16 CFR 1700, etc.). If there are no changes, clearly state so in your cover letter. Any changes require our review before final approval and the goal date for our review will be set accordingly.

Until we issue a final approval letter, this NDA is not deemed approved.

Please note that this drug product may not be marketed in the United States without final agency approval under Section 505 of the Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under Section 501 of the Act and 21 U.S.C. 331(d).

We remind you that if you intend to market this product in the United States after the period of patent and exclusivity protection expires, final approval of your application will require that you comply with all applicable U.S. legislation, including the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), which requires that all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration contain a pediatric assessment unless this requirement is waived, deferred, or inapplicable. A pediatric assessment contains data gathered from pediatric studies using appropriate formulations for each age group for which the assessment is required, and other data that are adequate to: 1.) assess the

safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and 2.) support dosing and administration for each pediatric subpopulation for which the product has been assessed to be safe and effective. You must also join the antiretroviral pregnancy registry at that time and make the appropriate labeling change that references the existence of the pregnancy registry.

We also remind you that you are expected to comply with the reporting requirements provided in 21 CFR 314.80 and 314.81. If the product is to be mass distributed in developing countries, a system of collecting and reporting adverse drug reactions by the distributor would be desirable (e.g., through governmental or nongovernmental agencies distributing the products).

If you have any questions, please call Monica Zeballos, Pharm.D., Program Coordinator, at (301) 796-0840 or via email at [monica.zeballos@fda.hhs.gov](mailto:monica.zeballos@fda.hhs.gov).

Sincerely yours,

*{See appended electronic signature page}*

Jeffrey S. Murray, M.D., M.P.H.  
Deputy Director  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling  
Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JEFFREY S MURRAY  
02/09/2018